PBX-7 payload-based ADC / PinotBio - LARVOL DELTA

Pinotbio unveils ADC pipeline PBX-7 series at 2nd ADC Toxicity Summit in US (Korea Biomedical Review) - "The dual MoA approach involves a single drug acting through two different mechanisms simultaneously to enhance therapeutic efficacy. The PBX-7 series payloads developed by Pinotbio inhibit Topoisomerase I (Top 1), similar to existing Camptothecin compounds, while also suppressing the expression of anti-apoptotic proteins....By moderately inhibiting Top 1 and strongly suppressing anti-apoptotic protein expression, the PBX-7 series maximizes anticancer effects while minimizing toxicity....Anti-apoptotic proteins, which aid in cancer cell survival and proliferation, are overexpressed in cancer cells but are scarce in normal cells. Therefore, targeting these proteins reduces the risk of side effects."

Preclinical • Oncology

Pinotbio releases preclinical results of new drug and linker at AACR 2024 (Korea Biomedical Review) - "Pinotbio is increasing its competitiveness on the global stage by emphasizing effectiveness and safety by combining the 'PBX-7 Series' and 'sequential cleavage linker'...Pinotbio, an ADC platform company, said Monday that it unveiled preclinical results of its ADC platform at the American Association for Cancer Research (AACR) 2024 in San Diego, Calif...According to the presentation, the PBX-7 Series demonstrated superior anticancer efficacy and excellent safety profile compared to Enhertu in various preclinical models. In an animal model implanted with a breast cancer cell line (JIMT-1) that had developed resistance to Roche's HER2-targeting ADC Kadcyla compared to Enhertu....Safety testing also showed excellent results in primate model toxicity, with no adverse effects observed at doses up to 30 mg/kg."

Preclinical • Breast Cancer • Oncology • Solid Tumor